Robert Hornby

Tozaro is developing a novel suite of reagents to help transform the development and manufacture of viral vectors in cell and gene therapy. Operating at the intersection of chemistry and biology, Tozaro’s smart polymers are evolving existing analytical and purification processes to realize a future where advanced therapies are accessible to all.

ULEMCo are pioneers of technologies that enable commercial vehicles to run off hydrogen. Focussed on customers that operate HGVs and LGVs, they provide practical solutions for the deployment of hydrogen vehicles, here and now, that will deliver significant reduction in fleet-wide carbon emissions. For all business enquiries, please contact: info@ulemco.com

Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.

Next generation programmable cell therapies

Yorkshire based Med Tech company specialising in Orthopaedics. A small company planning on making a big impact !

LUNAC Therapeutics is a spin out from the University of Leeds, UK and is pursuing the discovery of next generation oral anticoagulant therapies with a reduced risk of causing bleeding compared to current treatments. The business is founded on IP generated by Professor Helen Philippou (Professor of Translational Medicine in the Faculty of Medicine and Health at the University of Leeds) and Dr Richard Foster (Associate Professor at the University of Leeds), built on a decade of academic research into FXIIa in association with some of the world’s leading supporters of scientific and medical research, including the Wellcome Trust, British Heart Foundation and the UK’s Medical Research Council.

Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery. Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing tools to address the challenges of working with machine learning and quantum simulations in drug discovery. This strategy significantly improves the quality of new drugs being produced, as well as reduces discovery time. Our advisors and partners include leading academics and providers in the fields of quantum computing, AI and machine learning and drug discovery. In addition to our in-house discovery programs, we are interested in drug discovery collaborations with pharmaceutical and biotech companies seeking new approaches to novel, first in class, best in class or next generation inhibitors for validated or intractable enzyme targets.

MGISS independently advise on the smarter use of Geospatial data, technology and the digital transformation of field operations, taking organisations on a journey from asset Location to Insight. MGISS is a multi-award-winning company that informs organisations in the smart use of geospatial data and technologies to enable strategic asset management techniques. MGISS delivers innovative geospatial solutions that significantly improve the resilience, efficiency and performance of Utility, Infrastructure and Environmental assets. MGISS’s primary purpose is to support critical infrastructure operators and their contractors to optimise asset performance based on an ‘accurate and authoritative version of the data truth’ by providing solutions that locate, capture, validate and use infrastructure asset data. MGISS was recently ranked at number four in the North West Tech 50 disruptive companies creating innovative technology solutions and as one of the top 21 companies in mapping software.

Tozaro is developing a novel suite of reagents to help transform the development and manufacture of viral vectors in cell and gene therapy. Operating at the intersection of chemistry and biology, Tozaro’s smart polymers are evolving existing analytical and purification processes to realize a future where advanced therapies are accessible to all.

ULEMCo are pioneers of technologies that enable commercial vehicles to run off hydrogen. Focussed on customers that operate HGVs and LGVs, they provide practical solutions for the deployment of hydrogen vehicles, here and now, that will deliver significant reduction in fleet-wide carbon emissions. For all business enquiries, please contact: info@ulemco.com

Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.

The growth ecommerce platform. With all the automations, integrations, and conversations you need, make Shopblocks the heart of your business.